Sodium-dependent glucose (co-) transporter (SGLT) Inhibitors

Summary

Product description

The Competitive Intelligence Report Sodium-Dependent Glucose (Co)Transporter (SGLT) Inhibitors as of November 2008 provides a competitor analysis in the development pipeline of novel SGLT inhibitors for treatment of type 2 diabetes.

Sodium-dependent glucose (co)transporters (SGLT are specifically expressed in the intestines (SGLT-1) and kidneys (SGLT-1). Inhibitors of SGLT-1 suppress absorption of glucose from the gut, while SGLT-2 inhibitors block the reabsorptoin of glucose from the renal filtrate. Thus, SGLT inhibitors might be complementary approaches to traditional antidiabetics intervening with glucose metabolism. Most of the currently developed SGLT inhibitors are selective for SGLT-2, a minority is directed at SGLT-1 or SGLT-1/2. Although the most advanced SGLT-inhibitor now is in phase III clinical development, a high clinical stage drop-out rate characterizes the research and development efforts of novel SGLT inhibitors. At least ten SGLT inhibitors are in clinical development, predominantly by bigger pharmaceutical companies and many originating from Japan.

The report provides a compilation of current active and discontinued projects in research and development of novel SGLT-2, SGLT-1 and SGLT-1/2 inhibitors. Competitor projects are listed in a tabular format providing information on:

• Drug Codes,
• Target / Mechanism of Action,
• Class of Compound,
• Company,
• Product Category,
• Indication,
• R&D Stage and
• additional comments with a hyperlink leading to the source of information.

Contents

• Index
  • SGLT-2 Inhibitors
  • SGLT-1 and SGLT-1/2 Inhibitors
  • Corporate SGLT Inhibitor R&D Pipelines
  • About La Merie